A Phase II Prospective Trial of mXELOXIRI Reintroduction for mCRC

NCT04508452 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

91

Enrollment

OTHER

Sponsor class

Conditions

Unresectable Metastatic Colorectal Carcinoma

Interventions

DRUG: Capecitabine-Oxaliplatin-Irinotecan-Bevacizumab Combination

Sponsor

First Affiliated Hospital of Zhejiang University